- Home
- EA vs KVUE Comparison
EA vs KVUE Comparison
Compare EA & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EA
- KVUE
- Stock Information
- Founded
- EA 1982
- KVUE 2022
- Country
- EA United States
- KVUE United States
- Employees
- EA N/A
- KVUE N/A
- Industry
- EA Computer Software: Prepackaged Software
- KVUE Specialty Chemicals
- Sector
- EA Technology
- KVUE Consumer Discretionary
- Exchange
- EA Nasdaq
- KVUE Nasdaq
- Market Cap
- EA 41.4B
- KVUE 46.2B
- IPO Year
- EA N/A
- KVUE 2023
- Fundamental
- Price
- EA $147.80
- KVUE $21.78
- Analyst Decision
- EA Buy
- KVUE Hold
- Analyst Count
- EA 17
- KVUE 13
- Target Price
- EA $165.59
- KVUE $22.67
- AVG Volume (30 Days)
- EA 2.2M
- KVUE 12.8M
- Earning Date
- EA 02-04-2025
- KVUE 02-06-2025
- Dividend Yield
- EA 0.51%
- KVUE 3.77%
- EPS Growth
- EA 7.92
- KVUE N/A
- EPS
- EA 3.89
- KVUE 0.55
- Revenue
- EA $7,409,000,000.00
- KVUE $15,459,000,000.00
- Revenue This Year
- EA $4.88
- KVUE $2.89
- Revenue Next Year
- EA $5.86
- KVUE $2.80
- P/E Ratio
- EA $37.97
- KVUE $39.39
- Revenue Growth
- EA N/A
- KVUE N/A
- 52 Week Low
- EA $124.92
- KVUE $17.67
- 52 Week High
- EA $168.50
- KVUE $24.46
- Technical
- Relative Strength Index (RSI)
- EA 26.56
- KVUE 32.80
- Support Level
- EA $162.27
- KVUE $21.42
- Resistance Level
- EA $167.71
- KVUE $22.48
- Average True Range (ATR)
- EA 2.94
- KVUE 0.60
- MACD
- EA -2.54
- KVUE -0.18
- Stochastic Oscillator
- EA 5.14
- KVUE 12.81
About EA Electronic Arts Inc.
Electronic Arts is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, EA Sports FC (formerly FIFA), Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.